-
Product Insights
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy. The Hairy Cell Leukemia pipeline drugs market research report outlays comprehensive information on the Hairy Cell Leukemia targeted therapeutics, complete with analysis...
-
Product Insights
Pandemic Influenza – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Pandemic Influenza - Global Clinical Trials Review, H2, 2021" provides an overview of Pandemic Influenza Clinical trials scenario. This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Wheezing Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Wheezing Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Wheezing Clinical trials scenario. This report provides top line data relating to the clinical trials on Wheezing. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Dermatomyositis Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dermatomyositis Clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Pandemic Influenza – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Pandemic Influenza Global Clinical Trials Review, H2, 2020" provides an overview of Pandemic Influenza Clinical trials scenario. This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Track & Monitor
PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Sector Analysis
Hepatocellular Carcinoma: Competitive Landscape to 2026
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is the sixth most common type of cancer, accounts for around 90% of primary liver cancers, and is third most common cause of cancer mortality. HCC is particularly aggressive and has a poor survival rate (five-year survival <5%) and therefore remains an important public health issue worldwide. In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure (from crops), liver cirrhosis and hemochromatosis,...
-
Sector Analysis
PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026
Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories:...
-
Sector Analysis
PharmaPoint: Prostate Cancer – Global Drug Forecast and Market Analysis to 2026
The prostate cancer market is expected to experience a moderate growth between 2016 and 2026. The main drivers of growth will be the expected label expansion of second-generation hormonal agents into hormone-sensitive disease and non-metastatic castration resistant prostate cancer (nmCRPC), and the launch and uptake of nine new premium-priced therapies. Until now, the hormone sensitive setting has been dominated by the use of cheap first-generation hormonal agents, with the use of premium-priced second-generation hormonal agents (Xtandi and Zytiga) limited to...
-
Track & Monitor
Monthly Mining Industry Deals Review – August 2018
GlobalData's “Monthly Mining Industry Deals Review – August 2018” report is an essential source of data and trend analysis on M&A (mergers, acquisitions, and asset transactions), in the mining industry. The report provides detailed comparative monthly data on the number of deals and their value, sub-divided into deal types, by status, by region, and country. The report also highlights top buyers and sellers by region in addition to top announced and completed deals by value globally.